No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Relief Therapeutics Holding GAAP EPS of -CHF 1.37, Revenue of CHF 9.83B
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Completes Strategic Transition With Sale of GOLIKE Rights Ex-US
Relief Therapeutics Provides Update on Potential Transaction With Renexxion
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa